Key Highlights

  • Phase 3 VELA Week 52 data showed 67.2% of patients achieving HiSCR75, 33.1% HiSCR100, and 26% achieving inflammatory remission, outperforming competing IL-17 agents by over 10 percentage points across response endpoints.
  • BLA submission to the FDA is planned for end of September 2026, with Priority Review requested, and an Investor Day webcast is being held today at 8:00 AM EST to discuss data and commercialisation strategy.
  • MLTX is trading at $23.05 pre-market June 22, up 20.01% from the June 18 close of $19.21, with first commercial launch targeted for 2027 if Priority Review is not granted.

MoonLake Immunotherapeutics (NASDAQ: MLTX) is trading at $23.05 pre-market June 22, up 20.01% from the June 18 close of $19.21. MoonLake is a clinical-stage biopharmaceutical company developing sonelokimab, a tri-specific IL-17A and IL-17F inhibiting Nanobody for inflammatory skin and joint diseases including hidradenitis suppurativa, psoriatic arthritis, and axial spondyloarthritis.

The catalyst is the release of Week 52 Phase 3 VELA results for sonelokimab in moderate-to-severe hidradenitis suppurativa. Across the combined VELA-1 and VELA-2 trials, 67.2% of patients achieved HiSCR75 and 33.1% achieved HiSCR100, with 26% reaching inflammatory remission defined as 100% reduction in abscesses, nodules, and draining tunnels. Quality of life improvements were substantial, with the HiSQOL mean score shifting from severe to mild impairment, and 46.5% of patients experiencing a marked reduction in pain. Critically, results exceeded those observed in prior Phase 3 programs with competing IL-17 agents by over ten percentage points across HiSCR75, HiSCR100, and inflammatory remission endpoints, supporting the best-in-class framing. The VELA-TEEN adolescent study showed nearly 68% achieving HiSCR75 at Week 24 with no new safety signals.

MoonLake plans to submit the BLA to the FDA by end of September 2026, including adolescent data. Priority Review has been requested, which if granted could bring the launch approximately one quarter forward relative to the standard 2027 timeline. An Investor Day webcast is scheduled for today at 8:00 AM EST, covering data, proposed label strategy, and H2 2026 milestones including readout of the IZAR-1 Phase 3 trial in psoriatic arthritis.

Valuation and Risk Considerations

MLTX reports a negative EPS of $3.88 without a conventional P/E ratio. The 52-week range of $5.95 to $62.75 reflects the long journey from earlier-stage development to registrational readout. Key risks include FDA acceptance of the BLA, Priority Review outcome, and commercial launch execution in a competitive dermatology market.

Conclusion

MoonLake's pre-market surge reflects a registrational-quality data package that delivers on the best-in-class hypothesis, paired with a clear and near-term regulatory pathway.